

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

and the state of t				
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/088,549	08/02/2002	Erik Nielsen	DEBE:007US 6658	
7590 04/12/2004			EXAMINER	
Steven L Highlander			SAUCIER, SANDRA E	
Fulbright & Jaworski 600 Congress Avenue Suite2400 Austin, TX 78701			ART UNIT	PAPER NUMBER
			1651	•
			DATE MAILED: 04/12/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary						
		10/088,549	NIELSEN ET AL.			
		Examiner	Art Unit			
		Sandra Saucier	1651			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to comm	unication(s) filed on					
2a) This action is FINAL		action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)	m(s) is/are withdra e allowed. e rejected. e objected to.	wn from consideration.				
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
, —						
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) 1) Notice of References Cited (PT 2) Notice of Draftsperson's Patent 3) Information Disclosure Statemer Paper No(s)/Mail Date		4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:				

Application/Control Number: 10/088,549

Art Unit: 1651

DETAILED ACTION

Claims 14-39 are pending and subject to election of species.

This application contains claims directed to the following patentably distinct species of the claimed invention:

First, please chose either determining (a) GPTase function (claim 24) or (b) determining GTPase interaction with a GTPase effector/regulator molecule (claim 25). If (a) is chosen please further choose one of (a1) measuring GTP/GDP nucleotide exchange, (a2) GTP hydrolysis, (a3) endosomal motility or (a4) endosomal trafficking.

Second, please choose the substance screened from (c) a peptide, (d) cytokine, (e) hormone, (f) antibody, (g) organometallic compound, (h) β -hydroxycarboxylic acid, (i) inorganic acid, (j) metallocene complex, (k) nucleic acid. If peptide (b) is chosen, please further chose one from claims 34 and 35, of either 8 (c1), 10 (c2) or 12 (c3) amino acid residues in length. If nucleic acid (k) is chosen, please further choose one of Seq. ID # 1 (k1), 3 (k2), 5 (k3), 7 (k4), 9 (k5), 11 (k6), 13 (k7) or 15 (k8) as in claim 38.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 14 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP \S 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly

Application/Control Number: 10/088,549

Art Unit: 1651

admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Saucier whose telephone number is (571) 272-0922. The examiner can normally be reached on Monday, Tuesday, Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, M. Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sandra Saucier

Primary Examiner

Art Unit 1651